Immix Biopharma, Inc. Common Stock
IMMXImmix Biopharma, Inc. (IMMX) is a biotechnology company focused on developing and commercializing innovative therapies in the field of immuno-oncology. The company's primary goal is to advance treatments that enhance the immune system's ability to target and eliminate cancer cells, with a particular emphasis on therapies that can improve patient outcomes in oncology.
Company News
Immix Biopharma successfully closed a $100 million public offering of common stock and pre-funded warrants, raising approximately $93.7 million with support from leading biotechnology institutional investors and mutual funds.
Immix Biopharma priced an underwritten offering of common stock and pre-funded warrants, expecting to raise $100 million to fund NXC-201 development and corporate operations through mid-2027.
Immix Biopharma announced promising Phase 2 clinical trial results for NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis, with a 75% complete response rate and potential to increase to 95%.
Immix Biopharma's CAR-T cell therapy NXC-201 demonstrated positive clinical results in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate and a favorable safety profile.
Immix Biopharma's subsidiary Nexcella has received an $8 million grant from the California Institute for Regenerative Medicine to support the clinical development of its CAR-T therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.
